Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nogapendekin alfa inbakicept + Ad5 HPV
- Development stage
- Unknown
- Lead developer
- ImmunityBio
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Viral Vectors → Gene Addition/Replacement → Gene Therapies, Cytokines & Interferons → Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
Nogapendekin alfa inbakicept + Ad5 HPV (QUILT-3.100) is an investigational combination immunotherapy developed by ImmunityBio for the treatment of human papillomavirus (HPV)-associated cancers, specifically second-line head and neck squamous cell carcinoma (HNSCC). The regimen consists of nogapendekin alfa inbakicept (N-803), an IL-15 superagonist complex that stimulates NK cells and CD8+ T cells, and an adenovirus type 5 (Ad5)-vectored vaccine designed to induce immune responses against HPV-specific tumor antigens. By combining a potent cytokine stimulator with a targeted viral-vectored vaccine, the therapy aims to enhance the recruitment and activation of tumor-specific T cells to overcome the immunosuppressive tumor microenvironment.
- Other names
- N-803 + Ad5 HPVNAI + Ad5 HPVnogapendekin alfa inbakicept plus adenovirus-vectored HPV vaccine
02
Targets
HPV16 E6 oncoproteinIL2RG (Interleukin-2 receptor gamma subunit)HPV16 E7 (Human papillomavirus 16 E7 protein)
Beyond the preview
Go deeper on nogapendekin alfa inbakicept + Ad5 HPV.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nogapendekin alfa inbakicept + Ad5 HPV.